All In Biotech

Drug Trial Radar · NCT03768427

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese Participants

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

454

Actual

Start

May 27, 2019

Primary completion

Mar 17, 2021

Study completion Apr 1, 2021

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Dec 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants. The primary hypothesis is that MK-0653C 10/10 mg is superior to atorvastatin 20 mg in percent change from baseline in LDL-C to 12 weeks after treatment.

Conditions

  • Hypercholesterolemia

Interventions

  • EZ 10 mg/Ator 10 mgCombination product

    FDC of EZ10 mg/Ator 10mg

  • EZ 10 mg/Ator 20 mgCombination product

    FDC of EZ10 mg/Ator 20mg

  • AtorvastatinDrug

    Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets

  • Placebo for FDC EZ/AtorDrug

    A single placebo tablet administered orally QD for 84 days

  • Placebo for atorvastatinDrug

    Two placebo tablets matching atorvastatin administered orally QD for 84 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in LDL-C at Week 12Time frame: Baseline (Day 1) and Week 12

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Baotou Medical College ( Site 0025)

    Baotou, Anhui, China

  • Beijing Anzhen Hospital. Capital Medical University ( Site 0001)

    Beijing, Anhui, China

  • Aero Space center hospital ( Site 0003)

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital ( Site 0005)

    Beijing, Beijing Municipality, China

  • Chongqing General Hospital ( Site 0037)

    Chongqing, Chongqing Municipality, China

  • Lanzhou University Second Hospital ( Site 0041)

    Lanzhou, Gansu, China

  • Guangdong General Hospital ( Site 0006)

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital.Sun Yat-sen University ( Site 0007)

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 0008)

    Guangzhou, Guangdong, China

  • Daqing Oilfield General Hospital ( Site 0010)

    Daqing, Heilongjiang, China

  • The first affiliated Hospital of Harbin Medical University ( Site 0009)

    Haerbin, Heilongjiang, China

  • The Third Xiangya Hospital of Central South University ( Site 0013)

    Changsha, Hunan, China

  • Hunan Provincial People's Hospital ( Site 0011)

    Changsha, Hunan, China

  • Zhongda Hospital Southeast University ( Site 0045)

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Nanjing Medical University ( Site 0020)

    Nanjing, Jiangsu, China

  • First Affiliated Hospital of Soochow University ( Site 0048)

    Suzhou, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University ( Site 0017)

    Xuzhou, Jiangsu, China

  • Subei People's Hospital ( Site 0040)

    Yangzhou, Jiangsu, China

  • Second Affiliated Hospital of Nanchang University ( Site 0038)

    Nanchang, Jiangxi, China

  • Ji Lin Province People Hospital ( Site 0016)

    Changchun, Jilin, China

  • China-Japan Union Hospital of Jilin University ( Site 0015)

    Changchun, Jilin, China

  • Central People s Hospital of Siping ( Site 0046)

    Siping, Jilin, China

  • The People's Hospital of Liaoning Province-Cardiovascular ( Site 0022)

    Shenyang, Liaoning, China

  • Zhongshan Hospital Fudan University ( Site 0049)

    Shanghai, Shanghai Municipality, China

  • Shanghai Tongji Hospital ( Site 0031)

    Shanghai, Shanghai Municipality, China

  • Tianjin Union Medicine Centre ( Site 0032)

    Tianjin, Tianjin Municipality, China

  • People s Hospital of Lishui City ( Site 0036)

    Lishui, Zhejiang, China

  • Ningbo First Hospital ( Site 0042)

    Ningbo, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province ( Site 0035)

    Taizhou, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0034)

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.